Navigation Links
The Silent Killer, Ovarian Cancer on Your Cancer Today (TM)
Date:10/11/2007

NEWPORT BEACH, Calif., Oct. 11 /PRNewswire/ -- Each year, more than 90,000 U.S. women will be diagnosed with some form of gynecological cancer. Although the overall death rate for most of these cancers is falling, death from ovarian cancer has increased slightly.

Dr. Stan Wasbin, Medical Director of Your Cancer Today, (http://www.yourcancertoday.com) provides an overview of gynecological cancer, stressing the importance of early detection.

Your Cancer Today interviews Dr. Barbara Goff, Director of the Gynecologic Cancer Division at the University of Washington. Dr. Goff describes the risk factors and warning signs of endometrial, cervical and ovarian cancer. Dr. Goff reports that for the first time, professionals are identifying ovarian cancer symptoms and explains what women, and their doctors, should be on the alert for.

Treating brain cancer patients with a single drug often produces disappointing results. Your Cancer Today interviews Dr. Ronald A. DePinho, director of the Center for Applied Cancer Science at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School. Dr. DePinho recently completed a study-published in Science -- that suggested that many brain tumors should be genetically profiled and treated with multiple drugs.

Additional information from this week's episode:

-- When detected early, ovarian cancer usually can be cured. Yet most

cases are found late, when the 5-year survival rate is only 20-30%.

-- The oncologist's most successful screening test, the PAP smear, has

dropped the incidence of cervical cancer by more than 70%!

Dr. Goff discusses ovarian cancer symptoms

http://www.yourcancertoday.com/Cancers/Ovarian-Epithelial-Cancer/161

Dr. Ronald A. DePinho interview on his brain cancer s
'/>"/>

SOURCE Your Cancer Today
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Water - The silent killer!!!
2. Sleeping sickness - a silent killer
3. Risks for Silent Strokes
4. AIDS - The ‘silent but lethal tsunami’ of Asia
5. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
6. Domestic Violence: The Silent Killer of Women Worldwide
7. Silent Shortage Of Psychiatrists growing in the U.S.
8. Sperms not silent in the Female reproductive Tract
9. Carotid Stenting Can Help Patients With Silent Disease
10. Beware Of A Silent Killer Called Haemophilia
11. Diabetes, The Silent Killer of New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)... -- ViroPharma Incorporated,(Nasdaq: VPHM ) tod...ntal,Biologics License Application (sBLA) to the ...ze(TM) C1 Inhibitor (human) as a treatment for acu... The sBLA is based on a re-analysis and resubmis...nt study of Cinryze and interim data from an ongoi...
(Date:12/1/2008)... ETHICON, Inc., a Johnson & Johnson company, a...re of its Professional Wound Care business to One ...on are not being disclosed. , , Under the t...cquired the Professional Wound Care product portfo...s as PROMOGRAN Matrix Wound Dressing, TIELLE Hydro...
(Date:12/1/2008)...als, commitment and resources , , MOND...cism that it has done a poor job safeguarding the ...istration released a report Monday detailing its e...mportant changes in 2008 was the agency,s initiati...cal health departments to protect the food supply,...
(Date:12/1/2008)...ndation announces the 2008 winners of the Lee C. H...ipients, Dr. Gerard Karsenty of the Columbia Unive...weig of Rockefeller University received the award ...ure and control of rheumatic diseases. , Dr. Ka...opment and function of the skeletal system. A grad...
Breaking Medicine News(10 mins):Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 3Health News:FDA Touts Efforts to Enhance Food Safety 2Health News:FDA Touts Efforts to Enhance Food Safety 3Health News:FDA Touts Efforts to Enhance Food Safety 4
...g to a Danish study conducted by Dr. Morten Anders...d colleagues it was found that doctors //who took ...end to prescribe the sponsor’s drugs. The study re...al Association. The research team said that this i...
...g to a study conducted by Yale university research...ter part of one's life resulted in an increased ra...people between the age group of 51 to 61 years. Th...pational and Environmental Medicine journal. Out o...
...n Cancer Support of UK has taken a strong campaign... conducted that said that in Scotland people spent...ital during treatment which is ?318 in Wales. The...parking costs be made free or subsidized. "These ...
...Stone, the killer of Lin and Megan Russell has pet...ake his mental health report// public since it wou... is is serving life for the two murders committed ...Clayton QC said that the parts of the mental healt...
Other Medicine News:
(Date:11/26/2008).... 26 Children whose eye...antly increased risk of developing mental illness ...yo Clinic study published this month in Pediatrics... Pediatrics. , , The retrospective study ex...rabismus (misaligned eyes) and compared them with ...
(Date:11/25/2008)...espondents against expanding statin use broadly in...LS, N.J., Nov. 25 JUPITER, a clini...rdiovascular risk of healthy patients with elevate...lder adults, according to a national poll directed...took part in the online poll conducted by medical ...
(Date:11/25/2008)...RNewswire-FirstCall/ -- CardioVascular,BioTherape...today that it has,dosed the first patient in Nort...ical trial to treat patients with severe coronary ...eatment of CORonary heart Disease) trial will incl...lled doses in approximately 120,patients with sev...
(Date:11/24/2008)... innovation leadership and long-term commitment to...ov. 24 Schering-Plough C...l update on boceprevir, its lead investigational o...ase III development. The company believes bocepre...est-in-class protease inhibitor for treating chron...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9UNC scientists turn human skin cells into insulin producing cells 4935 1UNC scientists turn human skin cells into insulin producing cells 4935 2Final Patient Enrolled In Large Data Registry of Incisionless Gastric Pouch and Stoma Reduction Procedure 26533 1Final Patient Enrolled In Large Data Registry of Incisionless Gastric Pouch and Stoma Reduction Procedure 26533 2Final Patient Enrolled In Large Data Registry of Incisionless Gastric Pouch and Stoma Reduction Procedure 26533 3Final Patient Enrolled In Large Data Registry of Incisionless Gastric Pouch and Stoma Reduction Procedure 26533 4The Childrens Hospital of Philadelphia Erects the Final Beam of its Newest Research Building 26529 1The Childrens Hospital of Philadelphia Erects the Final Beam of its Newest Research Building 26529 2The Childrens Hospital of Philadelphia Erects the Final Beam of its Newest Research Building 26529 3Multi Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3080 1Multi Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3080 2Multi Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3080 3Multi Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3080 4Multi Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3080 5
...--Apr 26, 2007 - Northfield,Laboratories Inc. (Nas...rch organization has informed the Company that the... III trauma trial with,PolyHeme(R), the Company,s ...bstitute, will not be complete until May., About N...nc. is a leader in developing an,oxygen-carrying r...
...emonstrates dramatic,benefits of adding Diovan to ...to superior outcomes for,Diovan patients , , , ... from the independent,Jikei Heart Study, published...d pressure lowering medication Diovan® to,conv... in,cardiovascular events and a 40% reduction in s...
Other Medicine Technology:Northfield Laboratories Investor Update 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7
...nverted microscopy from Zeiss. It has outstanding ..., with innovative condensers and optimized fluores...cated documentation and adaptation options, outsta... And Axiovert 200 M, fully motorized, gives you th...
... hallmark of these stereozoom fluorescent microsco... The top (incident) circular 9W fluorescent ring l... shadows while remaining cool to the touch. Binocu...10x to 44x zoom magnification or high-power 20x to...
...esigned for scientific microscope imaging applicat...ras provides high-resolution, full-color images an...E 1394) high-speed interface. This "live" previewi...lance and auto exposure operations to further enha...
...nce photomicrography system that greatly simply ta...t difficult specimens. Designed with real life in ...complex problem of fluorescence photomicrography. ...he system utilizes special programs designed to ea...
Medicine Products: